Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) Sees Significant Decrease in Short Interest

Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) was the recipient of a significant drop in short interest in February. As of February 28th, there was short interest totalling 38,900 shares, a drop of 68.0% from the February 13th total of 121,400 shares. Based on an average daily volume of 153,700 shares, the days-to-cover ratio is currently 0.3 days. Approximately 0.2% of the shares of the stock are sold short.

Hedge Funds Weigh In On Bolt Biotherapeutics

Several institutional investors have recently added to or reduced their stakes in BOLT. FMR LLC grew its holdings in Bolt Biotherapeutics by 33.2% during the 3rd quarter. FMR LLC now owns 115,386 shares of the company’s stock valued at $75,000 after buying an additional 28,773 shares in the last quarter. Citadel Advisors LLC purchased a new position in Bolt Biotherapeutics during the 4th quarter valued at approximately $42,000. Millennium Management LLC purchased a new position in Bolt Biotherapeutics during the 4th quarter valued at approximately $25,000. Squarepoint Ops LLC purchased a new position in Bolt Biotherapeutics during the 4th quarter valued at approximately $26,000. Finally, Velan Capital Investment Management LP purchased a new position in Bolt Biotherapeutics during the 4th quarter valued at approximately $27,000. Hedge funds and other institutional investors own 86.70% of the company’s stock.

Bolt Biotherapeutics Stock Performance

NASDAQ BOLT opened at $0.40 on Thursday. The stock has a market capitalization of $15.42 million, a PE ratio of -0.24 and a beta of 0.94. The business has a 50 day simple moving average of $0.50 and a two-hundred day simple moving average of $0.57. The company has a debt-to-equity ratio of 0.21, a current ratio of 3.16 and a quick ratio of 3.16. Bolt Biotherapeutics has a 1-year low of $0.40 and a 1-year high of $1.56.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reiterated a “neutral” rating on shares of Bolt Biotherapeutics in a research report on Wednesday, November 13th. Five investment analysts have rated the stock with a hold rating, Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $3.50.

Bolt Biotherapeutics Company Profile

Bolt Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company’s lead product candidate BDC-1001, which is in clinical development for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer.